The GDF2 Knockout AGS Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of AGS cells bearing a targeted disruption in the GDF2 gene, which encodes the bone morphogenetic protein BMP9. This loss-of-function tool enables comprehensive investigation of BMP9-dependent cellular processes. By incorporating a diverse pool of edited alleles, the polyclonal knockout format captures population-level phenotypic effects and avoids clonal selection bias, making it suitable for pooled genetic screens and studies requiring heterogeneous gene inactivation.
The parental AGS cell line is a human gastric adenocarcinoma epithelial line derived from a primary tumor, widely utilized in gastric cancer research to study tumor cell biology, drug sensitivity, and interactions with Helicobacter pylori. Its transformed epithelial origin provides a robust and physiologically relevant model for dissecting signaling pathways that drive gastric tumorigenesis and shape the tumor microenvironment.
GDF2 (BMP9) is a secreted ligand of the transforming growth factor-beta (TGF-??) superfamily that primarily signals via the type I receptor ACVRL1 (ALK1) and type II receptors BMPR2 or ACVR2A. Ligand engagement induces phosphorylation of the intracellular effectors SMAD1, SMAD5, and SMAD8, which then translocate to the nucleus and transcriptionally regulate key target genes including ID1, ID2, and HAMP. ID1 and ID2 encode inhibitors of differentiation that promote vascular morphogenesis and angiogenic sprouting, while HAMP encodes hepcidin, the master endocrine regulator of systemic iron homeostasis. Pathway output is further modulated by the co-receptor Endoglin and by diffusible antagonists such as Noggin and Gremlin. Through this molecular framework, GDF2 exerts critical control over angiogenesis and iron metabolism.
In the AGS gastric adenocarcinoma context, this GDF2 knockout model offers a unique opportunity to dissect BMP9 functions beyond its canonical endothelial roles. Gastric cancers frequently exhibit deregulated TGF-??/BMP signaling and altered iron handling, and disrupting GDF2 in these epithelial cells illuminates autocrine and paracrine contributions to tumor-stroma crosstalk, angiogenic factor release, and hepcidin-mediated iron sequestration. The system thus enables targeted studies of how BMP9 loss impacts gastric tumor cell behavior and microenvironmental communication without confounding endothelial sources.
These polyclonal knockout cells are well-suited for functional assays including Western blot detection of phosphorylated SMAD1/5/8, quantitative RT-PCR for ID1, ID2, and HAMP transcripts, and hepcidin ELISA to assess iron-regulatory output. Conditioned media from these cells can be employed in endothelial tube formation assays or ALK1 receptor binding studies to evaluate paracrine angiogenic signals. Research applications encompass hereditary hemorrhagic telangiectasia modeling, pulmonary arterial hypertension, iron overload disorders, gastric cancer progression, and high-throughput drug discovery targeting the ALK1/Endoglin signaling pathway. For further technical details, please contact Ascent Research.
